Using genetic tests to predict immunotherapy response in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-small cell lung cancer (NSCLC) that has spread to other parts of the body.
- You have a tumor sample (from surgery or biopsy) that was taken before you started any cancer treatment like chemotherapy or radiation.
- You are in fairly good health, able to perform daily activities with some help if needed (ECOG score 0-2).
- Your blood counts, liver, and kidney function are within normal ranges.
- You have not received prior systemic therapy (chemo or targeted pills) for your metastatic lung cancer.
- You have agreed to have your medical data and tumor sample used for research and have signed a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This study looks at genetic information from tumor tissue of people with non-small cell lung cancer who had immunotherapy before surgery but still had some cancer cells left. The goal is to understand why the cancer did not completely respond to treatment.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
This trial uses special tests (like looking at genes and proteins) to better understand which patients with non-small cell lung cancer (NSCLC) will benefit most from immunotherapy given before surgery. It aims to create a tool to predict treatment success.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial tests whether a “liquid biopsy” blood test can help predict how well first immunotherapy will work for people with stage IV lung cancer. It may help doctors choose the most effective treatment strategy sooner.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.